Lixte Biotech Hlds (LIXT) Stock Price, Quote & News

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology

Sector: Healthcare

Phone: 631 830 7092

Fax: 631 982 5050

Website: lixte.com

Address:

680 East Colorado Boulevard, Suite 180, Pasadena, United States

NetworkNewsWire Mar. 20 at 7:34 PM

$LIXT Advances PP2A Inhibition Strategy in Evolving Oncology Landscape https://ibn.fm/aIFxa

0 · Reply

NetworkNewsWire Mar. 16 at 7:06 PM

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy $LIXT https://ibn.fm/60DFY

0 · Reply

NetworkNewsWire Mar. 13 at 5:07 PM

$LIXT Expands LB 100 Development Through Strategic Academic and Pharma Partnerships https://ibn.fm/caDQt

0 · Reply

Seraphina25 Mar. 11 at 7:36 PM

$LIXT looking good

0 · Reply

topstockalerts Mar. 11 at 7:33 PM

$LIXT Early stage biotech that traders watch around clinical progress updates. Any meaningful data release could quickly change sentiment.

0 · Reply

NetworkNewsWire Mar. 6 at 8:34 PM

TinyGemsBreaks – $LIXT Adds Innovative LiGHT Therapy to Pipeline https://ibn.fm/W6gD5

0 · Reply

NetworkNewsWire Mar. 6 at 7:38 PM

$LIXT Advances Lead Compound in Tumor Immunogenicity Research https://ibn.fm/1M5UP

0 · Reply

NetworkNewsWire Mar. 2 at 8:32 PM

Liora, a subsidiary of $LIXT, Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy https://ibn.fm/iwdyO

0 · Reply

BillionerOfKing Feb. 26 at 3:26 AM

$LIXT Current Stock Price: $3.12

0 · Reply

NetworkNewsWire Feb. 23 at 8:26 PM

$LIXT Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care https://ibn.fm/driax

0 · Reply

LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

Jan 21, 2026, 8:00 AM EST - 2 months ago

DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Jan 20, 2026, 8:00 AM EST - 2 months ago

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Dec 23, 2025, 8:00 AM EST - 3 months ago

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

Dec 8, 2025, 8:30 AM EST - 3 months ago

LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities

Dec 3, 2025, 11:00 AM EST - 3 months ago

LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology

Dec 3, 2025, 8:00 AM EST - 3 months ago

LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers

Nov 25, 2025, 8:30 AM EST - 4 months ago

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

Oct 29, 2025, 8:00 AM EDT - 5 months ago

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

Oct 16, 2025, 8:00 AM EDT - 5 months ago

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Sep 16, 2025, 8:30 AM EDT - 6 months ago

LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)

Sep 15, 2025, 5:40 PM EDT - 6 months ago

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)

Sep 10, 2025, 4:05 PM EDT - 6 months ago

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

Sep 5, 2025, 8:35 AM EDT - 7 months ago

24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor

Sep 3, 2025, 8:00 AM EDT - 7 months ago

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

Aug 27, 2025, 8:15 AM EDT - 7 months ago

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

Aug 25, 2025, 8:05 AM EDT - 7 months ago

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

Aug 19, 2025, 11:18 AM EDT - 7 months ago

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

Aug 18, 2025, 8:00 AM EDT - 7 months ago

LIXTE Biotechnology Holdings Provides Corporate Update

Aug 14, 2025, 9:06 PM EDT - 7 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Aug 14, 2025, 8:05 AM EDT - 7 months ago

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

Aug 13, 2025, 8:49 AM EDT - 7 months ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

Aug 13, 2025, 7:30 AM EDT - 7 months ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

Jul 16, 2025, 8:05 AM EDT - 8 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 9, 2025, 5:15 PM EDT - 9 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 8:05 AM EDT - 9 months ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 8, 2025, 2:57 PM EDT - 9 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 2, 2025, 4:05 PM EDT - 9 months ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 9 months ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Mar 31, 2025, 8:30 AM EDT - 1 year ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 27, 2025, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Feb 25, 2025, 8:30 AM EST - 1 year ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 13, 2025, 10:35 AM EST - 1 year ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 1 year ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 10, 2025, 5:00 PM EST - 1 year ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Sep 4, 2024, 8:30 AM EDT - 1 year ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Aug 26, 2024, 8:30 AM EDT - 1 year ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 19, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 14, 2024, 10:50 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Jun 14, 2024, 11:00 AM EDT - 1 year ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 6, 2024, 8:30 AM EDT - 1 year ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 3, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

May 20, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 8, 2024, 9:25 AM EDT - 2 years ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Mar 21, 2024, 8:30 AM EDT - 2 years ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Feb 27, 2024, 8:30 AM EST - 2 years ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Feb 26, 2024, 8:30 AM EST - 2 years ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Jan 29, 2024, 8:30 AM EST - 2 years ago

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

NetworkNewsWire Mar. 20 at 7:34 PM

$LIXT Advances PP2A Inhibition Strategy in Evolving Oncology Landscape https://ibn.fm/aIFxa

0 · Reply

NetworkNewsWire Mar. 16 at 7:06 PM

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy $LIXT https://ibn.fm/60DFY

0 · Reply

NetworkNewsWire Mar. 13 at 5:07 PM

$LIXT Expands LB 100 Development Through Strategic Academic and Pharma Partnerships https://ibn.fm/caDQt

0 · Reply

Seraphina25 Mar. 11 at 7:36 PM

$LIXT looking good

0 · Reply

topstockalerts Mar. 11 at 7:33 PM

$LIXT Early stage biotech that traders watch around clinical progress updates. Any meaningful data release could quickly change sentiment.

0 · Reply

NetworkNewsWire Mar. 6 at 8:34 PM

TinyGemsBreaks – $LIXT Adds Innovative LiGHT Therapy to Pipeline https://ibn.fm/W6gD5

0 · Reply

NetworkNewsWire Mar. 6 at 7:38 PM

$LIXT Advances Lead Compound in Tumor Immunogenicity Research https://ibn.fm/1M5UP

0 · Reply

NetworkNewsWire Mar. 2 at 8:32 PM

Liora, a subsidiary of $LIXT, Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy https://ibn.fm/iwdyO

0 · Reply

BillionerOfKing Feb. 26 at 3:26 AM

$LIXT Current Stock Price: $3.12

0 · Reply

NetworkNewsWire Feb. 23 at 8:26 PM

$LIXT Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care https://ibn.fm/driax

0 · Reply

DunnoT Feb. 21 at 11:58 AM

Nice potential short term long opportunity for $NCI based on 4 similar events: [Ticker; End date] $KAVL 2022-02-15 $DFLI 2025-10-03 $LIXT 2025-07-03 $BTAI 2025-08-12 1) Expect a drop (-30 - 40%) 2) Re-test previous high (+50 - 70%) https://www.tradingview.com/chart/NCI/hxiiP7Jo-Similar-events-for-NCI/

0 · Reply

NetworkNewsWire Feb. 18 at 8:17 PM

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It $LIXT https://ibn.fm/u7L64

0 · Reply

NetworkNewsWire Feb. 18 at 7:57 PM

BioMedNewsBreaks – $LIXT Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary https://ibn.fm/iX7cH

0 · Reply

SpectralWick Feb. 18 at 9:03 AM

$LIXT Oncology microcap where dilution risk is constant; data quality and cash runway are everything.

0 · Reply

OfficialStocktwitsUser Feb. 17 at 9:39 PM

$LIXT RSI: 41.30, MACD: -0.1883 Vol: 0.31, MA20: 3.26, MA50: 3.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

YieldOptimizer Feb. 17 at 1:05 PM

$LIXT Pre-revenue lithium; speculative.

0 · Reply

optionravi Feb. 17 at 8:31 AM

$LIXT Pre-revenue lithium; speculative

0 · Reply

NetworkNewsWire Feb. 13 at 8:01 PM

$LIXT Focused on Dual Narratives of Scientific Progress, Social Engagement https://ibn.fm/LCsnH

0 · Reply

DavidScott Feb. 12 at 4:12 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $LIXT $LIDR $TROO $GEVO $KULR

1 · Reply

DavidScott Feb. 11 at 9:19 PM

$SUNE $CCHH $LIXT $LIDR $NCI = Great job everyone! The bulls had some good movement today, even with these turbulent market conditions this round. These were our main trades, and we are bullish and expecting even more momentum on these names again going into Thursday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🙌 Have a great day everybody! 🎉

0 · Reply

NetworkNewsWire Feb. 11 at 7:58 PM

BioMedNewsBreaks — $LIXT Bringing First-in-Class Approach to Chemo and Immunotherapy https://ibn.fm/dzPmt

0 · Reply

NetworkNewsWire Feb. 9 at 8:20 PM

$LIXT Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment https://ibn.fm/z39wf

0 · Reply

Market Cap	20.49M
Revenue (ttm)	0.00
Net Income (ttm)	-3.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	31,200
Avg Vol	64,186
Day's Range	N/A - N/A
Shares Out	7.48M
Stochastic %K	33%
Beta	0.86
Analysts	Strong Buy
Price Target	N/A